-
1
-
-
38549176118
-
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review
-
COI: 1:CAS:528:DC%2BD1cXhtV2it74%3D, PID: 18155297
-
Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279. doi:10.1016/j.pharmthera.2007.10.001
-
(2008)
Pharmacol Ther
, vol.117
, pp. 244-279
-
-
Tracey, D.1
Klareskog, L.2
Sasso, E.H.3
-
2
-
-
0032553664
-
New treatments for rheumatoid arthritis
-
COI: 1:STN:280:DyaK1M%2FktlWnuw%3D%3D, PID: 9825708
-
Pisetsky D (1998) New treatments for rheumatoid arthritis. Health News 4:3
-
(1998)
Health News
, vol.4
, pp. 3
-
-
Pisetsky, D.1
-
3
-
-
0031755494
-
Biological insights from clinical trials with anti-TNF therapy
-
COI: 1:CAS:528:DyaK1cXmvVShtbo%3D, PID: 9836378
-
Feldmann M, Charles P, Taylor P, Maini RN (1998) Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 20:211–228. doi:10.1007/BF00832008
-
(1998)
Springer Semin Immunopathol
, vol.20
, pp. 211-228
-
-
Feldmann, M.1
Charles, P.2
Taylor, P.3
Maini, R.N.4
-
4
-
-
84864505241
-
Enbrel patent surfaces
-
COI: 1:CAS:528:DC%2BC38XitVWrs7o%3D, PID: 22318016
-
Harrison C (2012) Enbrel patent surfaces. Nat Biotechnol 30:123. doi:10.1038/nbt0212-123
-
(2012)
Nat Biotechnol
, vol.30
, pp. 123
-
-
Harrison, C.1
-
5
-
-
84863435547
-
The advent of biosimilar therapies in rheumatology—“O brave new world
-
COI: 1:CAS:528:DC%2BC38XpsVKltL0%3D, PID: 22664834
-
Scheinberg MA, Kay J (2012) The advent of biosimilar therapies in rheumatology—“O brave new world”. Nat Rev Rheumatol 8:430–436. doi:10.1038/nrrheum.2012.84
-
(2012)
Nat Rev Rheumatol
, vol.8
, pp. 430-436
-
-
Scheinberg, M.A.1
Kay, J.2
-
6
-
-
84861876412
-
Can next-generation antibodies offset biosimilar competition?
-
COI: 1:CAS:528:DC%2BC38XnslOjt7k%3D, PID: 22653202
-
Mullard A (2012) Can next-generation antibodies offset biosimilar competition? Nat Rev Drug Discov 11:426–428. doi:10.1038/nrd3749
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 426-428
-
-
Mullard, A.1
-
7
-
-
0030669930
-
Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis
-
COI: 1:CAS:528:DyaK2sXnsFahtbg%3D, PID: 9391689
-
Murray KM, Dahl SL (1997) Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 31:1335–1338
-
(1997)
Ann Pharmacother
, vol.31
, pp. 1335-1338
-
-
Murray, K.M.1
Dahl, S.L.2
-
8
-
-
0033144422
-
Etanercept: a review of its use in rheumatoid arthritis
-
COI: 1:CAS:528:DyaK1MXkt1GnsLs%3D, PID: 10400407
-
Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57:945–966
-
(1999)
Drugs
, vol.57
, pp. 945-966
-
-
Jarvis, B.1
Faulds, D.2
-
9
-
-
0033768517
-
Etanercept (Enbrel): update on therapeutic use
-
COI: 1:CAS:528:DC%2BD3cXos1ylsr0%3D, PID: 11053088
-
Spencer-Green G (2000) Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 59:i46–i49. doi:10.1136/ard.59.suppl_1.i46
-
(2000)
Ann Rheum Dis
, vol.59
, pp. i46-i49
-
-
Spencer-Green, G.1
-
10
-
-
0037261293
-
Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis
-
PID: 12641492
-
Culy CR, Keating GM (2003) Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. BioDrugs 17:139–145. doi:10.2165/00063030-200317020-00006
-
(2003)
BioDrugs
, vol.17
, pp. 139-145
-
-
Culy, C.R.1
Keating, G.M.2
-
11
-
-
0036731162
-
Therapy for ankylosing spondylitis: new treatment modalities
-
COI: 1:STN:280:DC%2BD38nks12hsA%3D%3D, PID: 12406431
-
Braun J, Breban M, Maksymowych WP (2002) Therapy for ankylosing spondylitis: new treatment modalities. Best Pract Res Clin Rheumatol 16:631–651. http://dx.doi.org/10.1053/berh.2002.0245
-
(2002)
Best Pract Res Clin Rheumatol
, vol.16
, pp. 631-651
-
-
Braun, J.1
Breban, M.2
Maksymowych, W.P.3
-
12
-
-
0022369998
-
Tumor necrosis factor (TNF)
-
COI: 1:STN:280:DyaL28%2FhvVyltQ%3D%3D, PID: 2413547
-
Old LJ (1985) Tumor necrosis factor (TNF). Science 230:630–632
-
(1985)
Science
, vol.230
, pp. 630-632
-
-
Old, L.J.1
-
13
-
-
0035056003
-
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
-
COI: 1:CAS:528:DC%2BD3MXivFKgtbg%3D, PID: 11244034
-
Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196. doi:10.1146/annurev.immunol.19.1.163
-
(2001)
Annu Rev Immunol
, vol.19
, pp. 163-196
-
-
Feldmann, M.1
Maini, R.N.2
-
14
-
-
0026644298
-
Anti-TNF ameliorates joint disease in murine collagen-induced arthritis
-
COI: 1:CAS:528:DyaK38XmsV2rsb4%3D, PID: 1409699
-
Williams RO, Feldmann M, Maini RN (1992) Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784–9788. doi:10.1073/pnas.89.20.9784
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 9784-9788
-
-
Williams, R.O.1
Feldmann, M.2
Maini, R.N.3
-
15
-
-
0026677361
-
Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
-
COI: 1:CAS:528:DyaK3sXhtVShs7w%3D
-
Piguet PF, Grau GE, Vesin C et al (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. J Immunol 77:510–514
-
(1992)
J Immunol
, vol.77
, pp. 510-514
-
-
Piguet, P.F.1
Grau, G.E.2
Vesin, C.3
-
16
-
-
0026039673
-
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis
-
COI: 1:CAS:528:DyaK38XhtVCiurw%3D, PID: 1721867
-
Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031
-
(1991)
EMBO J
, vol.10
, pp. 4025-4031
-
-
Keffer, J.1
Probert, L.2
Cazlaris, H.3
-
17
-
-
85099638486
-
® (etanercept)
-
® (etanercept)
-
-
-
-
18
-
-
84939878747
-
European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products. Accessed 26 December 2013
-
European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf. Accessed 26 December 2013
-
-
-
-
19
-
-
0033574147
-
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
-
COI: 1:CAS:528:DyaK1MXitFChs7Y%3D, PID: 10075615
-
Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478–486
-
(1999)
Ann Intern Med
, vol.130
, pp. 478-486
-
-
Moreland, L.W.1
Schiff, M.H.2
Baumgartner, S.W.3
-
20
-
-
0034729950
-
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
-
COI: 1:CAS:528:DC%2BD3cXls1Cksr8%3D, PID: 10972371
-
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390. doi:10.1016/S0140-6736(00)02530-7
-
(2000)
Lancet
, vol.356
, pp. 385-390
-
-
Mease, P.J.1
Goffe, B.S.2
Metz, J.3
VanderStoep, A.4
Finck, B.5
Burge, D.J.6
-
21
-
-
76149102966
-
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
-
PID: 20124563
-
Sterry W, Ortonne J-P, Kirkham B et al (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147. doi:10.1136/bmj.c147
-
(2010)
BMJ
, vol.340
, pp. c147
-
-
Sterry, W.1
Ortonne, J.-P.2
Kirkham, B.3
-
22
-
-
84864407871
-
Etanercept in psoriatic arthritis
-
COI: 1:CAS:528:DC%2BC38Xht12mu7zJ, PID: 22751599
-
Spadaro A, Lubrano E, Ferrara N, Scarpa R (2012) Etanercept in psoriatic arthritis. J Rheumatol Suppl 89:74–76. doi:10.3899/jrheum.120250
-
(2012)
J Rheumatol Suppl
, vol.89
, pp. 74-76
-
-
Spadaro, A.1
Lubrano, E.2
Ferrara, N.3
Scarpa, R.4
-
23
-
-
77952823783
-
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
-
COI: 1:CAS:528:DC%2BC3cXpsVKnsbk%3D, PID: 20590580
-
Weger W (2010) Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 160:810–820. doi:10.1111/j.1476-5381.2010.00702.x
-
(2010)
Br J Pharmacol
, vol.160
, pp. 810-820
-
-
Weger, W.1
-
24
-
-
0037007683
-
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
-
COI: 1:CAS:528:DC%2BD38Xjt1Shs70%3D, PID: 11986408
-
Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349–1356. doi:10.1056/NEJMoa012664
-
(2002)
N Engl J Med
, vol.346
, pp. 1349-1356
-
-
Gorman, J.D.1
Sack, K.E.2
Davis, J.C.3
-
25
-
-
0242411795
-
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial
-
COI: 1:CAS:528:DC%2BD3sXpvVygtb0%3D, PID: 14613288
-
Davis JC, Van Der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236. doi:10.1002/art.11325
-
(2003)
Arthritis Rheum
, vol.48
, pp. 3230-3236
-
-
Davis, J.C.1
Van Der Heijde, D.2
Braun, J.3
-
26
-
-
78651361751
-
Anti-TNF a therapy in ankylosing spondylitis: symptom control and structural damage modification
-
Andreu JL, Otón T, Sanz J (2011) Anti-TNF a therapy in ankylosing spondylitis: symptom control and structural damage modification. Reum Clin 7:51–55. doi:10.1016/j.reuma.2009.03.007
-
(2011)
Reum Clin
, vol.7
, pp. 51-55
-
-
Andreu, J.L.1
Otón, T.2
Sanz, J.3
-
27
-
-
0030456356
-
Epidemiology of chronic arthritis in childhood
-
COI: 1:STN:280:DyaK2s7ktlOqsA%3D%3D, PID: 8989803
-
Oen KG, Cheang M (1996) Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 26:575–591. http://dx.doi.org/10.1016/S0049-0172(96)80009-6
-
(1996)
Semin Arthritis Rheum
, vol.26
, pp. 575-591
-
-
Oen, K.G.1
Cheang, M.2
-
28
-
-
0036709328
-
Etanercept in systemic juvenile idiopathic arthritis
-
COI: 1:STN:280:DC%2BD38nlt1Slug%3D%3D, PID: 12412209
-
Russo RA, Katsicas MM, Zelazko M (2002) Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 20:723–726
-
(2002)
Clin Exp Rheumatol
, vol.20
, pp. 723-726
-
-
Russo, R.A.1
Katsicas, M.M.2
Zelazko, M.3
-
29
-
-
37349096323
-
Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001–2004
-
PID: 18050185
-
Sacks JJ, Helmick CG, Luo YH et al (2007) Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001–2004. Arthritis Rheum 57:1439–1445. doi:10.1002/art.23087
-
(2007)
Arthritis Rheum
, vol.57
, pp. 1439-1445
-
-
Sacks, J.J.1
Helmick, C.G.2
Luo, Y.H.3
-
30
-
-
36549065772
-
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence
-
PID: 17570009
-
Gartlehner G, Hansen RA, Jonas BL et al (2008) Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 27:67–76. doi:10.1007/s10067-007-0654-6
-
(2008)
Clin Rheumatol
, vol.27
, pp. 67-76
-
-
Gartlehner, G.1
Hansen, R.A.2
Jonas, B.L.3
-
31
-
-
0034673697
-
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group
-
COI: 1:CAS:528:DC%2BD3cXit1Smu7k%3D, PID: 10717011
-
Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769. doi:10.1056/NEJM200003163421103
-
(2000)
N Engl J Med
, vol.342
, pp. 763-769
-
-
Lovell, D.J.1
Giannini, E.H.2
Reiff, A.3
-
32
-
-
0036151142
-
Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period
-
COI: 1:CAS:528:DC%2BD38Xht1yrsLs%3D, PID: 11796406
-
Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61:171–173. doi:10.1136/ard.61.2.171
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 171-173
-
-
Kietz, D.A.1
Pepmueller, P.H.2
Moore, T.L.3
-
33
-
-
0037388345
-
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
-
COI: 1:CAS:528:DC%2BD3sXjtlKns7g%3D, PID: 12687553
-
Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093–1101. doi:10.1002/art.10885
-
(2003)
Arthritis Rheum
, vol.48
, pp. 1093-1101
-
-
Quartier, P.1
Taupin, P.2
Bourdeaut, F.3
-
34
-
-
0037370938
-
Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study
-
COI: 1:CAS:528:DC%2BD3sXisVGmurk%3D, PID: 12594111
-
Lahdenne P, Vahasalo PH (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245–247. doi:10.1136/ard.62.3.245
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 245-247
-
-
Lahdenne, P.1
Vahasalo, P.H.2
-
35
-
-
5044227291
-
Prolonged efficacy of etanercept in refractory enthesitis-related arthritis
-
COI: 1:CAS:528:DC%2BD2cXps1agt7c%3D, PID: 15468375
-
Henrickson M, Reiff A (2004) Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 31:2055–2061
-
(2004)
J Rheumatol
, vol.31
, pp. 2055-2061
-
-
Henrickson, M.1
Reiff, A.2
-
36
-
-
9644255827
-
The German etanercept registry for treatment of juvenile idiopathic arthritis
-
COI: 1:CAS:528:DC%2BD2cXhtFaktbjJ, PID: 15115709
-
Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638–1644. doi:10.1136/ard.2003.014886
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1638-1644
-
-
Horneff, G.1
Schmeling, H.2
Biedermann, T.3
-
37
-
-
22244479674
-
Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy
-
COI: 1:CAS:528:DC%2BD2MXnsl2gtrY%3D, PID: 15986366
-
Tse SM, Burgos-Vargas R, Laxer RM (2005) Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 52:2103–2108. doi:10.1002/art.21121
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2103-2108
-
-
Tse, S.M.1
Burgos-Vargas, R.2
Laxer, R.M.3
-
38
-
-
58249084593
-
Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies
-
COI: 1:CAS:528:DC%2BC3cXht1CltbbN, PID: 19070529
-
Sulpice M, Deslandre CJ, Quartier P (2009) Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 76:24–27. doi:10.1016/j.jbspin.2008.03.008
-
(2009)
Joint Bone Spine
, vol.76
, pp. 24-27
-
-
Sulpice, M.1
Deslandre, C.J.2
Quartier, P.3
-
39
-
-
82755162854
-
Attainment of inactive disease status following initiation of TNF-alpha inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease
-
COI: 1:CAS:528:DC%2BC38Xht1aitLc%3D, PID: 22089470
-
Donnithorne KJ, Cron RQ, Beukelman T (2011) Attainment of inactive disease status following initiation of TNF-alpha inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol 38:2675–2681. doi:10.3899/jrheum.110427
-
(2011)
J Rheumatol
, vol.38
, pp. 2675-2681
-
-
Donnithorne, K.J.1
Cron, R.Q.2
Beukelman, T.3
-
40
-
-
84899911643
-
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
-
Horneff G, Burgos-Vargas R, Constantin T et al (2013) Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 1–9. doi:10.1136/annrheumdis-2012-203046
-
(2013)
Ann Rheum Dis
, pp. 1-9
-
-
Horneff, G.1
Burgos-Vargas, R.2
Constantin, T.3
-
41
-
-
1242263852
-
TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis
-
COI: 1:STN:280:DC%2BD2c7hsFOrsw%3D%3D, PID: 15005015
-
Gudbrandsdottir S, Larsen R, Sørensen LK et al (2004) TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 22:118–124
-
(2004)
Clin Exp Rheumatol
, vol.22
, pp. 118-124
-
-
Gudbrandsdottir, S.1
Larsen, R.2
Sørensen, L.K.3
-
42
-
-
10844244616
-
Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis
-
COI: 1:CAS:528:DC%2BD2MXmt1GnsQ%3D%3D, PID: 15794196
-
Gudbrandsdottir S, Bliddal H, Petri A et al (2004) Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scand J Rheumatol 33:385–388. doi:10.1080/03009740410000921
-
(2004)
Scand J Rheumatol
, vol.33
, pp. 385-388
-
-
Gudbrandsdottir, S.1
Bliddal, H.2
Petri, A.3
-
43
-
-
69449088802
-
Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes
-
COI: 1:CAS:528:DC%2BD1MXht1WhtLjM, PID: 19714631
-
Meusch U, Rossol M, Baerwald C et al (2009) Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 60:2612–2621. doi:10.1002/art.24778
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2612-2621
-
-
Meusch, U.1
Rossol, M.2
Baerwald, C.3
-
44
-
-
63749093322
-
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
-
COI: 1:CAS:528:DC%2BD1MXksVWgurs%3D, PID: 19188093
-
Kaymakcalan Z, Sakorafas P, Bose S et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131:308–316. doi:10.1016/j.clim.2009.01.002
-
(2009)
Clin Immunol
, vol.131
, pp. 308-316
-
-
Kaymakcalan, Z.1
Sakorafas, P.2
Bose, S.3
-
45
-
-
47349097005
-
Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis
-
COI: 1:CAS:528:DC%2BD1cXht1amu73E, PID: 18645606
-
Fries W, Muja C, Crisafulli C et al (2008) Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci 5:169–180. doi:10.7150/ijms.5.169
-
(2008)
Int J Med Sci
, vol.5
, pp. 169-180
-
-
Fries, W.1
Muja, C.2
Crisafulli, C.3
-
46
-
-
79960147677
-
Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients
-
COI: 1:CAS:528:DC%2BC3MXptVWnsL8%3D, PID: 21593236
-
Herman S, Zurgil N, Machlav S et al (2011) Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients. Clin Vaccine Immunol 18:1077–1082. doi:10.1128/CVI.00061-11
-
(2011)
Clin Vaccine Immunol
, vol.18
, pp. 1077-1082
-
-
Herman, S.1
Zurgil, N.2
Machlav, S.3
-
47
-
-
12344297311
-
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report
-
COI: 1:CAS:528:DC%2BD2MXht1Kisb4%3D, PID: 15641091
-
Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61–72. doi:10.1002/art.20764
-
(2005)
Arthritis Rheum
, vol.52
, pp. 61-72
-
-
Catrina, A.I.1
Trollmo, C.2
af Klint, E.3
-
48
-
-
84859476232
-
Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis
-
COI: 1:CAS:528:DC%2BC38XotVOgu7o%3D, PID: 22422498
-
Makrygiannakis D, Catrina AI (2012) Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis. J Rheumatol 39:679–685. doi:10.3899/jrheum.110974
-
(2012)
J Rheumatol
, vol.39
, pp. 679-685
-
-
Makrygiannakis, D.1
Catrina, A.I.2
-
49
-
-
84887859669
-
Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics
-
COI: 1:CAS:528:DC%2BC3sXhsFeqtrnE, PID: 23952252
-
Giragossian C, Clark T, Piché-Nicholas N, Bowman C (2013) Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. Curr Drug Metab 14:764–790. doi:10.2174/13892002113149990099
-
(2013)
Curr Drug Metab
, vol.14
, pp. 764-790
-
-
Giragossian, C.1
Clark, T.2
Piché-Nicholas, N.3
Bowman, C.4
-
50
-
-
78651360674
-
Optimizing therapeutic antibody function: progress with Fc domain engineering
-
COI: 1:CAS:528:DC%2BC3MXjt12gsrk%3D, PID: 21033767
-
Kaneko E, Niwa R (2011) Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 25:1–11. doi:10.2165/11537830-000000000-00000
-
(2011)
BioDrugs
, vol.25
, pp. 1-11
-
-
Kaneko, E.1
Niwa, R.2
-
51
-
-
17644386569
-
Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
-
COI: 1:CAS:528:DC%2BD2MXkvVWmsbY%3D, PID: 15831771
-
Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490–497. doi:10.1177/0091270004273321
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 490-497
-
-
Zhou, H.1
-
52
-
-
84874656491
-
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
-
PID: 23399692
-
Van Schouwenburg PA, Rispens T, Wolbink GJ (2013) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9:164–172. doi:10.1038/nrrheum.2013.4
-
(2013)
Nat Rev Rheumatol
, vol.9
, pp. 164-172
-
-
Van Schouwenburg, P.A.1
Rispens, T.2
Wolbink, G.J.3
-
53
-
-
84885292454
-
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
-
PID: 23887439
-
Mok CC, van der Kleij D, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. doi:10.1007/s10067-013-2336-x
-
(2013)
Clin Rheumatol
-
-
Mok, C.C.1
van der Kleij, D.2
Wolbink, G.J.3
-
54
-
-
84860710411
-
Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy
-
COI: 1:CAS:528:DC%2BC38Xlslantrc%3D, PID: 22407289
-
Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 14:296–302. doi:10.1208/s12248-012-9340-y
-
(2012)
AAPS J
, vol.14
, pp. 296-302
-
-
Chirmule, N.1
Jawa, V.2
Meibohm, B.3
-
55
-
-
84882261762
-
Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis
-
Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 1–13. doi:10.1001/jamainternmed.2013.7430
-
(2013)
JAMA Intern Med
, pp. 1-13
-
-
Maneiro, J.R.1
Salgado, E.2
Gomez-Reino, J.J.3
-
56
-
-
77953658260
-
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions
-
PID: 20400861
-
Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256–265. doi:10.4161/mabs.2.3.11641
-
(2010)
MAbs
, vol.2
, pp. 256-265
-
-
Harding, F.A.1
Stickler, M.M.2
Razo, J.3
DuBridge, R.B.4
-
57
-
-
79851475357
-
Immunogenicity of protein therapeutics: the key causes, consequences and challenges
-
PID: 21487506
-
Baker MP, Reynolds HM, Lumicisi B, Bryson CJ (2010) Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1:314–322. doi:10.4161/self.1.4.13904
-
(2010)
Self Nonself
, vol.1
, pp. 314-322
-
-
Baker, M.P.1
Reynolds, H.M.2
Lumicisi, B.3
Bryson, C.J.4
-
58
-
-
85099638618
-
-
® (etanercept). Accessed 26 Nov 2013
-
® (etanercept). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_02_immunex.pdf. Accessed 26 Nov 2013
-
-
-
-
59
-
-
84939921763
-
The importance of pharmacovigilance—safety monitoring of medicinal products
-
World Health Organization WHO (2002) The importance of pharmacovigilance—safety monitoring of medicinal products, pp 3–44. http://apps.who.int/medicinedocs/en/d/Js4893e/. Accessed 26 Nov 2013
-
(2002)
pp 3–44
-
-
-
60
-
-
84865692521
-
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis
-
COI: 1:CAS:528:DC%2BC38XhsFamtb3J, PID: 22948700
-
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308:898–908. doi:10.1001/2012.jama.10857
-
(2012)
JAMA
, vol.308
, pp. 898-908
-
-
Lopez-Olivo, M.A.1
Tayar, J.H.2
Martinez-Lopez, J.A.3
-
61
-
-
84881484330
-
A case series of sarcoidosis with pulmonary involvement: various clinical and radiographic manifestations
-
Disayabutr S, Pattanaprichakul P, Ruangchira-Urai R (2013) A case series of sarcoidosis with pulmonary involvement: various clinical and radiographic manifestations. J Med Assoc Thail 96:888–897
-
(2013)
J Med Assoc Thail
, vol.96
, pp. 888-897
-
-
Disayabutr, S.1
Pattanaprichakul, P.2
Ruangchira-Urai, R.3
-
62
-
-
84893541344
-
Deep vein thrombosis and lung cancer in a patient with psoriasis under anti-tumor necrosis factor treatment: a case study. Dermatol Ther
-
Tatarkova I, Cetkovska P (2013) Deep vein thrombosis and lung cancer in a patient with psoriasis under anti-tumor necrosis factor treatment: a case study. Dermatol Ther. doi:10.1111/dth.12041
-
(2013)
doi:10.1111/dth.12041
-
-
Tatarkova, I.1
Cetkovska, P.2
-
63
-
-
84876983825
-
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis
-
PID: 23147755
-
Babino G, Esposito M, Mazzotta A et al (2013) Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis. Acta Derm Venereol 93:373–374. doi:10.2340/00015555-1477
-
(2013)
Acta Derm Venereol
, vol.93
, pp. 373-374
-
-
Babino, G.1
Esposito, M.2
Mazzotta, A.3
-
64
-
-
84939921765
-
-
US Food and Drug Administration (FDA) (2005) Guidance for industry—E2E pharmacovigilance planning. Accessed 26 Dec 2013
-
US Food and Drug Administration (FDA) (2005) Guidance for industry—E2E pharmacovigilance planning. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073107.pdf. Accessed 26 Dec 2013
-
-
-
-
65
-
-
84884719069
-
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
-
Senabre- JM, Santos-ramírez C, Santos-soler G et al (2013) Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence 7:961–972
-
(2013)
Patient Prefer Adherence
, vol.7
, pp. 961-972
-
-
Senabre-, J.M.1
Santos-Ramírez, C.2
Santos-Soler, G.3
-
66
-
-
84939921766
-
-
European Medicines Agency EMA (2014) Annex I—summary of product characteristics. Accessed 20 Feb 2014
-
European Medicines Agency EMA (2014) Annex I—summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000262/WC500027361.pdf. Accessed 20 Feb 2014
-
-
-
-
67
-
-
84939921767
-
Biosimilars
-
Biophoenix (2007) Biosimilars, biogenerics and follow-on biologics. http://www.biotechduediligence.com/uploads/6/3/6/7/6367956/biosimilars_biogenerics_fobs.pdf. Accessed 14 Jan 2014
-
(2007)
biogenerics and follow-on biologics
-
-
-
68
-
-
35548990601
-
Selection methods for high-producing mammalian cell lines
-
COI: 1:CAS:528:DC%2BD2sXpsFKnsL4%3D, PID: 17659798
-
Browne SM, Al-Rubeai M (2007) Selection methods for high-producing mammalian cell lines. Trends Biotechnol 25:425–432. doi:10.1016/j.tibtech.2007.07.002
-
(2007)
Trends Biotechnol
, vol.25
, pp. 425-432
-
-
Browne, S.M.1
Al-Rubeai, M.2
-
69
-
-
84871478745
-
Biosimilars: company strategies to capture value from the biologics market
-
Calo-Fernández B, Martínez-Hurtado JL (2012) Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals (Basel) 5:1393–1408. doi:10.3390/ph5121393
-
(2012)
Pharmaceuticals (Basel)
, vol.5
, pp. 1393-1408
-
-
Calo-Fernández, B.1
Martínez-Hurtado, J.L.2
-
70
-
-
8344224534
-
Characterizing biological products and assessing comparability following manufacturing changes
-
COI: 1:CAS:528:DC%2BD2cXptlSlsL8%3D, PID: 15529163
-
Chirino AJ, Mire-Sluis A (2004) Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22:1383–1391. doi:10.1038/nbt1030
-
(2004)
Nat Biotechnol
, vol.22
, pp. 1383-1391
-
-
Chirino, A.J.1
Mire-Sluis, A.2
-
71
-
-
84879463281
-
Analytical characterization of biosimilar antibodies and Fc-fusion proteins
-
COI: 1:CAS:528:DC%2BC3sXosVCiuro%3D
-
Beck A, Diemer H, Ayoub D et al (2013) Analytical characterization of biosimilar antibodies and Fc-fusion proteins. TrAC, Trends Anal Chem 48:81–95. doi:10.1016/j.trac.2013.02.014
-
(2013)
TrAC, Trends Anal Chem
, vol.48
, pp. 81-95
-
-
Beck, A.1
Diemer, H.2
Ayoub, D.3
-
72
-
-
0036366238
-
Practical approaches to protein formulation development
-
COI: 1:CAS:528:DC%2BD38XntFeltb0%3D, PID: 11987748
-
Chang BS, Hershenson S (2002) Practical approaches to protein formulation development. Pharm Biotechnol 13:1–25. doi:10.1007/978-1-4615-0557-0_1
-
(2002)
Pharm Biotechnol
, vol.13
, pp. 1-25
-
-
Chang, B.S.1
Hershenson, S.2
-
73
-
-
84869757230
-
Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products
-
PID: 23032066
-
Tan Q, Guo Q, Fang C et al (2012) Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. MAbs 4:761–774. doi:10.4161/mabs.22276
-
(2012)
MAbs
, vol.4
, pp. 761-774
-
-
Tan, Q.1
Guo, Q.2
Fang, C.3
-
74
-
-
69449095403
-
Biosimilar therapeutics-what do we need to consider?
-
COI: 1:CAS:528:DC%2BD1MXit1Cht7o%3D, PID: 19461855
-
Schellekens H (2009) Biosimilar therapeutics-what do we need to consider? NDT Plus 2:i27–i36. doi:10.1093/ndtplus/sfn177
-
(2009)
NDT Plus
, vol.2
, pp. i27-i36
-
-
Schellekens, H.1
-
75
-
-
84939921768
-
-
European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. Accessed 26 December 2013
-
European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf. Accessed 26 December 2013
-
-
-
-
77
-
-
82155188444
-
Biosimilars: a regulatory perspective from America
-
COI: 1:CAS:528:DC%2BC3MXmtlKlsrY%3D, PID: 21586106
-
Kay J (2011) Biosimilars: a regulatory perspective from America. Arthritis Res Ther 13:112. doi:10.1186/ar3310
-
(2011)
Arthritis Res Ther
, vol.13
, pp. 112
-
-
Kay, J.1
-
78
-
-
84939921770
-
-
US Food and Drug Administration (FDA) (2012) Guidance for industry scientific considerations in demonstrating biosimilarity to a reference product. Accessed 26 Dec 2013
-
US Food and Drug Administration (FDA) (2012) Guidance for industry scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 26 Dec 2013
-
-
-
-
79
-
-
84939921771
-
-
US Food and Drug Administration (FDA) (2012) Guidance for industry biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Accessed 26 Dec 2013
-
US Food and Drug Administration (FDA) (2012) Guidance for industry biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf. Accessed 26 Dec 2013
-
-
-
-
80
-
-
84939921772
-
-
US Food and Drug Administration (FDA) (2012) Guidance for industry quality considerations in demonstrating biosimilarity to a reference protein product. Accessed 26 Dec 2013
-
US Food and Drug Administration (FDA) (2012) Guidance for industry quality considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed 26 Dec 2013
-
-
-
-
81
-
-
84870921310
-
Potential regulatory and commercial environment for biosimilars in Latin America
-
Azevedo VF, Sandorff E, Siemak B, Halbert RJ (2012) Potential regulatory and commercial environment for biosimilars in Latin America. Value Heal Reg Issues 1:228–234
-
(2012)
Value Heal Reg Issues
, vol.1
, pp. 228-234
-
-
Azevedo, V.F.1
Sandorff, E.2
Siemak, B.3
Halbert, R.J.4
-
82
-
-
77954700058
-
Are we prepared to prescribe biosimilars?
-
PID: 21125158
-
Azevedo VF (2010) Are we prepared to prescribe biosimilars? Rev Bras Reumatol 50:221–224. http://dx.doi.org/10.1590/S0482-50042010000300002
-
(2010)
Rev Bras Reumatol
, vol.50
, pp. 221-224
-
-
Azevedo, V.F.1
-
83
-
-
84876470598
-
Biosimilars require scientifically reliable comparative clinical data
-
Azevedo VF (2013) Biosimilars require scientifically reliable comparative clinical data. Rev Bras Reum 53:127–131. http://dx.doi.org/10.1590/S0482-50042013000100013
-
(2013)
Rev Bras Reum
, vol.53
, pp. 127-131
-
-
Azevedo, V.F.1
-
84
-
-
84884211461
-
Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges
-
COI: 1:CAS:528:DC%2BC3sXmsFWrsL4%3D, PID: 23235959
-
Simoens S, Huys I (2013) Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges. Semin Thromb Hemost 39:250–257. doi:10.1055/s-0032-1328970
-
(2013)
Semin Thromb Hemost
, vol.39
, pp. 250-257
-
-
Simoens, S.1
Huys, I.2
-
85
-
-
84939921773
-
Biosimilars handbook, 2nd ed
-
European Genereric Medicines Association (EGA) (2011) Biosimilars handbook, 2nd ed. EGA. http://www.egagenerics.com/index.php?option=com_dtracker&filename=EGA_BIOSIMILARS_handbook_en.pdf&filetitle=EGA_BIOSIMILARS_handbook_en.pdf. Accessed 12 December 2013
-
(2011)
EGA
-
-
-
86
-
-
70449440279
-
WHO guidelines presage US biosimilars legislation?
-
COI: 1:CAS:528:DC%2BD1MXhtlOrur3F, PID: 19898430
-
Hodgson J (2009) WHO guidelines presage US biosimilars legislation? Nat Biotechnol 27:963–965. doi:10.1038/nbt1109-963a
-
(2009)
Nat Biotechnol
, vol.27
, pp. 963-965
-
-
Hodgson, J.1
-
87
-
-
77957723026
-
Biosimilar epoetins and other “follow-on” biologics: update on the European experiences
-
PID: 20706990
-
Jelkmann W (2010) Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol 85:771–780. doi:10.1002/ajh.21805
-
(2010)
Am J Hematol
, vol.85
, pp. 771-780
-
-
Jelkmann, W.1
-
88
-
-
84890242549
-
Clinical considerations for biosimilar antibodies
-
Mellstedt H (2013) Clinical considerations for biosimilar antibodies. EJC Suppl 11:1–11. doi:10.1016/S1359-6349(13)70001-6
-
(2013)
EJC Suppl
, vol.11
, pp. 1-11
-
-
Mellstedt, H.1
-
89
-
-
84991839837
-
Biosimilar DMARD in rheumatology: a general perspective with focus on India
-
Chopra A, Shankar S (2012) Biosimilar DMARD in rheumatology: a general perspective with focus on India. Indian J Rheumatol 7:89–96. doi:10.1016/j.injr.2012.04.005
-
(2012)
Indian J Rheumatol
, vol.7
, pp. 89-96
-
-
Chopra, A.1
Shankar, S.2
-
90
-
-
84860619510
-
®): a double-blind, single-dose, crossover study in healthy volunteers
-
COI: 1:CAS:528:DC%2BC38XhtVSqtLzN, PID: 22515513
-
®): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs 26(3):177–184. doi:10.2165/11631860-000000000-00000
-
(2012)
BioDrugs
, vol.26
, Issue.3
, pp. 177-184
-
-
Yi, S.1
Kim, S.E.2
Park, M.K.3
-
91
-
-
83455201580
-
Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers
-
COI: 1:CAS:528:DC%2BC3MXhs1CjtLvF, PID: 22088414
-
Gu N, Yi S, Kim T-E et al (2011) Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 33:2029–2037. doi:10.1016/j.clinthera.2011.10.022
-
(2011)
Clin Ther
, vol.33
, pp. 2029-2037
-
-
Gu, N.1
Yi, S.2
Kim, T.-E.3
-
93
-
-
84939921775
-
-
Brazilian Ministry of Health (2013) MS atrai investimentos de R$ 1 bilhão para a produção de biofármacos. [Portuguese]. Accessed 10 Dec 2013
-
Brazilian Ministry of Health (2013) MS atrai investimentos de R$ 1 bilhão para a produção de biofármacos. http://www.blog.saude.gov.br/index.php/programasecampanhas/33290-ministerio-da-saude-atrai-investimentos-para-a-producao-de-biofarmacos [Portuguese]. Accessed 10 Dec 2013
-
-
-
-
94
-
-
84939921776
-
-
Protalix Biotherapeutics (2013) PRX-106. Accessed 10 December 2013
-
Protalix Biotherapeutics (2013) PRX-106. http://www.protalix.com/development-pipeline/prx-106-autoimmune.asp. Accessed 10 December 2013
-
-
-
-
95
-
-
84939921777
-
-
Chemo (2013) Libbs and mAbxience sign agreement for biosimilars in Brazil. Accessed 16 Nov 2013
-
Chemo (2013) Libbs and mAbxience sign agreement for biosimilars in Brazil. http://www.chemogroup.com/2013/04/22/mabxience-libbs-signed-agreement-brasilia-2/. Accessed 16 Nov 2013
-
-
-
-
96
-
-
84939921778
-
-
Mabxience (2013) Four Biosimilars Compounds Reaching Clinical Stage in 2013. Accessed 14 November 2013
-
Mabxience (2013) Four Biosimilars Compounds Reaching Clinical Stage in 2013. http://www.mabxience.com/products/. Accessed 14 November 2013
-
-
-
-
97
-
-
80055051682
-
A non-innovator version of etanercept for treatment of arthritis
-
COI: 1:CAS:528:DC%2BC3MXhsVSksbrL, PID: 21996051
-
Maity S, Ullanat R, Lahiri S et al (2011) A non-innovator version of etanercept for treatment of arthritis. Biologicals 39:384–395. doi:10.1016/j.biologicals.2011.08.014
-
(2011)
Biologicals
, vol.39
, pp. 384-395
-
-
Maity, S.1
Ullanat, R.2
Lahiri, S.3
-
98
-
-
84875254370
-
The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein
-
COI: 1:CAS:528:DC%2BC38XhslCntbnF, PID: 23190454
-
Lee J-H, Cho JH, Yeo J et al (2013) The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein. Biologicals 41:77–83. doi:10.1016/j.biologicals.2012.09.001
-
(2013)
Biologicals
, vol.41
, pp. 77-83
-
-
Lee, J.-H.1
Cho, J.H.2
Yeo, J.3
-
99
-
-
84868243646
-
Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells
-
COI: 1:CAS:528:DC%2BC38Xhslejtb7E, PID: 23009882
-
Lee J-H, Yeo J, Park HS et al (2013) Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells. Protein Expr Purif 87:17–26. doi:10.1016/j.pep.2012.09.001
-
(2013)
Protein Expr Purif
, vol.87
, pp. 17-26
-
-
Lee, J.-H.1
Yeo, J.2
Park, H.S.3
-
100
-
-
84873635799
-
The role of biosimilars in the treatment of rheumatic diseases
-
PID: 23253920
-
Dörner T, Strand V, Castañeda-Hernández G et al (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328. doi:10.1136/annrheumdis-2012-202715
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 322-328
-
-
Dörner, T.1
Strand, V.2
Castañeda-Hernández, G.3
-
101
-
-
8344222959
-
How similar do “biosimilars” need to be?
-
COI: 1:CAS:528:DC%2BD2cXptlSltr8%3D, PID: 15529154
-
Schellekens H (2004) How similar do “biosimilars” need to be? Nat Biotechnol 22:1357–1359. doi:10.1038/nbt1104-1357
-
(2004)
Nat Biotechnol
, vol.22
, pp. 1357-1359
-
-
Schellekens, H.1
-
102
-
-
84867644293
-
Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china
-
COI: 1:CAS:528:DC%2BC38XhsFCku7zK, PID: 23056637
-
Wu B, Wilson A, Wang F et al (2012) Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS ONE 7:e47373. doi:10.1371/journal.pone.0047373
-
(2012)
PLoS ONE
, vol.7
, pp. e47373
-
-
Wu, B.1
Wilson, A.2
Wang, F.3
-
103
-
-
80055096139
-
Etanar therapy in real-life patients with rheumatoid arthritis
-
Rondon F, Bautista A, Salazar JC et al (2010) Etanar therapy in real-life patients with rheumatoid arthritis. Arthritis Rheum 62(10):1811. doi:10.1002/art.29576
-
(2010)
Arthritis Rheum
, vol.62
, Issue.10
, pp. 1811
-
-
Rondon, F.1
Bautista, A.2
Salazar, J.C.3
-
104
-
-
84939921779
-
-
Biosimilarnews (2013) Cipla launches first biosimilar etanercept in India. Accessed 26 Nov 2013
-
Biosimilarnews (2013) Cipla launches first biosimilar etanercept in India. http://www.biosimilarnews.com/cipla-launches-first-biosimilar-etanercept-in-india. Accessed 26 Nov 2013
-
-
-
-
105
-
-
84939921780
-
Comparative, randomized, simple blind to evaluate efficacy and safety of Infinitam® (etanercept), associated with methotrexate compared with Enbrel® (etanercept) associated with methotrexate in patients with moderate and severe rheumatoid arthritis. Program and abstracts of the European League Against Rheumatism (EULAR) Congress 2013; June 12-15, 2013; Madrid, Spain
-
Moctezuma JF, Martinez A, Enkerlin H et al (2013) Comparative, randomized, simple blind to evaluate efficacy and safety of Infinitam® (etanercept), associated with methotrexate compared with Enbrel® (etanercept) associated with methotrexate in patients with moderate and severe rheumatoid arthritis. Program and abstracts of the European League Against Rheumatism (EULAR) Congress 2013; June 12-15, 2013; Madrid, Spain. Abstract THU0208
-
(2013)
Abstract THU0208
-
-
Moctezuma, J.F.1
Martinez, A.2
Enkerlin, H.3
-
106
-
-
36448974120
-
Biotherapeutics in the era of biosimilars: what really matters is patient safety
-
PID: 18035862
-
Declerck PJ (2007) Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 30:1087–1092
-
(2007)
Drug Saf
, vol.30
, pp. 1087-1092
-
-
Declerck, P.J.1
-
107
-
-
84939921781
-
-
European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Accessed 15 Feb 2014
-
European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf. Accessed 15 Feb 2014
-
-
-
-
108
-
-
84862581676
-
Comparability and biosimilarity: considerations for the healthcare provider
-
COI: 1:CAS:528:DC%2BC38XovVWhtbs%3D, PID: 22519391
-
Lee JF, Litten JB, Grampp G (2012) Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 28:1053–1058. doi:10.1185/03007995.2012.686902
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 1053-1058
-
-
Lee, J.F.1
Litten, J.B.2
Grampp, G.3
-
109
-
-
84939921782
-
-
ICH Harmonised Tripartite Guideline (2004) Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. Accessed 26 Nov 2013
-
ICH Harmonised Tripartite Guideline (2004) Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed 26 Nov 2013
-
-
-
-
110
-
-
84883897104
-
Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products: letter to the editor
-
Hassett B, McMillen S, Fitzpatrick B (2014) Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products: letter to the editor. MAbs 5:624–625. doi:10.4161/mabs.25817
-
(2014)
MAbs
, vol.5
, pp. 624-625
-
-
Hassett, B.1
McMillen, S.2
Fitzpatrick, B.3
-
111
-
-
79953861167
-
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
-
COI: 1:CAS:528:DC%2BC3MXksVCrsbg%3D, PID: 21478841
-
Schiestl M, Stangler T, Torella C et al (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29:310–312. doi:10.1038/nbt.1839
-
(2011)
Nat Biotechnol
, vol.29
, pp. 310-312
-
-
Schiestl, M.1
Stangler, T.2
Torella, C.3
-
112
-
-
84939921783
-
-
European Medicines Agency (EMA) (2006) Refusal assessment report for Alpheon. Accessed 26 Nov 2013
-
European Medicines Agency (EMA) (2006) Refusal assessment report for Alpheon. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000585/WC500070792.pdf. Accessed 26 Nov 2013
-
-
-
-
113
-
-
85099638051
-
-
® in subjects with moderate to severe rheumatoid arthritis despite methotrexate therapy. Accessed 26 Nov 2013
-
® in subjects with moderate to severe rheumatoid arthritis despite methotrexate therapy. http://clinicaltrials.gov/show/NCT01895309. Accessed 26 Nov 2013
-
-
-
-
115
-
-
84939921786
-
-
NIH (2013) Study to demonstrate equivalent efficacy and to compare safety of biosimilar etanercept (GP2015) and Enbrel (EGALITY). Accessed 26 Nov 2013
-
NIH (2013) Study to demonstrate equivalent efficacy and to compare safety of biosimilar etanercept (GP2015) and Enbrel (EGALITY). http://clinicaltrials.gov/show/NCT01891864. Accessed 26 Nov 2013
-
-
-
-
116
-
-
84455208119
-
A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis
-
COI: 1:CAS:528:DC%2BC38XhtlSksQ%3D%3D, PID: 22196469
-
Chen D-Y, Lai N-S, Lu L-Y et al (2011) A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis. J Chin Med Assoc 74:544–551. doi:10.1016/j.jcma.2011.10.009
-
(2011)
J Chin Med Assoc
, vol.74
, pp. 544-551
-
-
Chen, D.-Y.1
Lai, N.-S.2
Lu, L.-Y.3
-
117
-
-
85099638005
-
-
®. Accessed 14 Jan 2014
-
®. http://clinicaltrials.gov/show/NCT01725620. Accessed 14 Jan 2014
-
-
-
-
118
-
-
84939921788
-
Comparison the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ
-
NIH (2012) Comparison the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. After subcutaneous injection in healthy male volunteers. http://clinicaltrials.gov/show/NCT01635686. Accessed 26 Nov 2013
-
(2012)
After subcutaneous injection in healthy male volunteers
-
-
-
119
-
-
84939921789
-
-
Biosciences C (2013) Coherus announces CHS-0214 (proposed etanercept biosimilar) meets primary endpoint in pivotal pharmacokinetic clinical study. Accessed 26 Nov 2013
-
Biosciences C (2013) Coherus announces CHS-0214 (proposed etanercept biosimilar) meets primary endpoint in pivotal pharmacokinetic clinical study. http://www.coherus.com/press-releases/coherus-announces-chs-0214-proposed-etanercept-biosimilar-meets-primary-endpoint-in-pivotal-pharmacokinetic-clinical-study/. Accessed 26 Nov 2013
-
-
-
|